Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment



Berhane, Sarah, Fox, Richard, Garcia-Finana, Marta ORCID: 0000-0003-4939-0575, Cucchetti, Alessandro and Johnson, Philip ORCID: 0000-0003-1404-0209
(2019) Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment. British Journal of Cancer, 121 (2). pp. 117-124.

[img] Text
sorafenib paper bjc revised clean.docx - Author Accepted Manuscript

Download (135kB)
[img] Text
supplementary file_updated.docx - Author Accepted Manuscript

Download (58kB)
[img] Text
Fig 1A-B.pdf - Author Accepted Manuscript

Download (66kB) | Preview
[img] Text
Fig 2A-B.pdf - Author Accepted Manuscript

Download (85kB) | Preview
[img] Text
Fig 3A-B.pdf - Author Accepted Manuscript

Download (88kB) | Preview
[img] Spreadsheet
Table 1.xlsx - Author Accepted Manuscript

Download (12kB)
[img] Spreadsheet
Table 2.xlsx - Author Accepted Manuscript

Download (11kB)
[img] Spreadsheet
Table 3.xlsx - Author Accepted Manuscript

Download (12kB)

Abstract

Background Sorafenib is the current standard of care for patients with advanced hepatocellular carcinoma (aHCC) and has been shown to improve survival by about 3 months compared to placebo. However, survival varies widely from under three months to over two years. The aim of this study was to build a statistical model that allows personalised survival prediction following sorafenib treatment. Methods We had access to 1130 patients undergoing sorafenib treatment for aHCC as part of the control arm for two phase III randomised clinical trials (RCTs). A multivariable model was built that predicts survival based on baseline clinical features. The statistical approach permits both group-level risk stratification and individual-level survival prediction at any given time point. The model was calibrated, and its discrimination assessed through Harrell’s c-index and Royston-Sauerbrei’s R2D. Results The variables influencing overall survival were vascular invasion, age, ECOG score, AFP, albumin, creatinine, AST, extra-hepatic spread and aetiology. The model-predicted survival very similar to that observed. The Harrell’s c-indices for training and validation sets were 0.72 and 0.70, respectively indicating good prediction. Conclusions Our model (‘PROSASH’) predicts patient survival using baseline clinical features. However, it will require further validation in a routine clinical practice setting.

Item Type: Article
Uncontrolled Keywords: Hepatocellular carcinoma, Liver cancer, Targeted therapies
Depositing User: Symplectic Admin
Date Deposited: 09 Aug 2019 10:42
Last Modified: 19 Jan 2023 00:35
DOI: 10.1038/s41416-019-0488-4
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3051320